Colesevelam as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus

June 23, 2017 updated by: Daiichi Sankyo, Inc.

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of WELCHOL as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus (T2DM)

The current study investigates colesevelam as add-on therapy to pioglitazone to improve glycemic control in subjects with type 2 diabetes mellitus not adequately controlled with pioglitazone monotherapy or pioglitazone in combination with either metformin or a sulfonylurea. The study will evaluate if colesevelam add-on to pioglitazone therapy for type 2 diabetes mellitus will be safe, well tolerated, and efficacious.

Study Overview

Status

Completed

Study Type

Interventional

Enrollment (Actual)

562

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35294
      • Birmingham, Alabama, United States, 35205
      • Birmingham, Alabama, United States, 35216
      • Montgomery, Alabama, United States, 36117
      • Montgomery, Alabama, United States, 36106
    • Arizona
      • Green Valley, Arizona, United States, 85614
      • Mesa, Arizona, United States, 85210
      • Phoenix, Arizona, United States, 85050
      • Tempe, Arizona, United States, 85282
      • Tempe, Arizona, United States, 85284
    • Arkansas
      • Searcy, Arkansas, United States, 72143
    • California
      • Buena Park, California, United States, 90620
      • Burbank, California, United States, 91505
      • Chino, California, United States, 91710
      • Garden Grove, California, United States, 92844
      • Huntington Park, California, United States, 90255
      • La Mirada, California, United States, 90638
      • Lincoln, California, United States, 95648
      • Lomita, California, United States, 90717
      • Los Gatos, California, United States, 95032
      • Modesto, California, United States, 95355
      • San Diego, California, United States, 92161
      • Santa Ana, California, United States, 92701
      • Tustin, California, United States, 92780
      • Walnut Creek, California, United States, 94598
    • Florida
      • Coral Gables, Florida, United States, 33134
      • DeLand, Florida, United States, 32720
      • Delray Beach, Florida, United States, 33484
      • Gulf Breeze, Florida, United States, 32561
      • Hialeah, Florida, United States, 33012
      • Jacksonville, Florida, United States, 32223
      • Kissimmee, Florida, United States, 34741
      • Miami, Florida, United States, 33175
      • Miami, Florida, United States, 33169
      • Miami, Florida, United States, 33135
      • Miami, Florida, United States, 33156
      • Miami, Florida, United States, 33183
      • New Port Richey, Florida, United States, 34652
      • Ocala, Florida, United States, 34471
      • Ormond Beach, Florida, United States, 32174
      • Pembroke Pines, Florida, United States, 33026
      • Pembroke Pines, Florida, United States, 33027
      • Pinellas Park, Florida, United States, 33781
      • Sanford, Florida, United States, 32771
      • Tampa, Florida, United States, 33607
      • Vero Beach, Florida, United States, 32960
      • Wellington, Florida, United States, 33449
      • Winter Haven, Florida, United States, 33880
      • Winter Park, Florida, United States, 32792
      • Winter Park, Florida, United States, 32789
    • Georgia
      • Columbus, Georgia, United States, 31904
      • Decatur, Georgia, United States, 30035
      • East Point, Georgia, United States, 30344
      • Marietta, Georgia, United States, 30066
      • Roswell, Georgia, United States, 30076
      • Stockbridge, Georgia, United States, 30281
      • Tucker, Georgia, United States, 30084
      • Waycross, Georgia, United States, 31501
    • Idaho
      • Nampa, Idaho, United States, 83686
    • Illinois
      • Arlington Heights, Illinois, United States, 60004
      • Chicago, Illinois, United States, 60607
    • Indiana
      • Bloomington, Indiana, United States, 47403
      • Evansville, Indiana, United States, 47714
      • LaPorte, Indiana, United States, 46350
      • South Bend, Indiana, United States, 46614
    • Kentucky
      • Crestview Hills, Kentucky, United States, 41017
      • Paducah, Kentucky, United States, 42003
    • Louisiana
      • Lafayette, Louisiana, United States, 70503
    • Maryland
      • Prince Frederick, Maryland, United States, 20678
      • Silver Spring, Maryland, United States, 20910
    • Massachusetts
      • New Bedford, Massachusetts, United States, 02740
    • Michigan
      • Southfield, Michigan, United States, 48034
    • Minnesota
      • Brooklyn Center, Minnesota, United States, 55430
    • Mississippi
      • Jackson, Mississippi, United States, 39216
      • Port Gibson, Mississippi, United States, 39150
    • Missouri
      • Kansas City, Missouri, United States, 64111
      • Saint Louis, Missouri, United States, 63141
    • Montana
      • Billings, Montana, United States, 59101
    • Nevada
      • Las Vegas, Nevada, United States, 89123
    • New Jersey
      • Belvidere, New Jersey, United States, 07823
      • Berlin, New Jersey, United States, 08009
      • Clifton, New Jersey, United States, 07013
      • Lumberton, New Jersey, United States, 08048
      • Mine Hill, New Jersey, United States, 07803
    • New York
      • New Windsor, New York, United States, 12553
      • North Massapequa, New York, United States, 11758
      • Tonawanda, New York, United States, 14150
      • West Seneca, New York, United States, 14224
    • North Carolina
      • Lexington, North Carolina, United States, 27293
      • Statesville, North Carolina, United States, 28625
    • Ohio
      • Cincinnati, Ohio, United States, 45219
      • Cincinnati, Ohio, United States, 45227
      • Cincinnati, Ohio, United States, 45245
      • Cleveland, Ohio, United States, 44122
      • Columbus, Ohio, United States, 43213
      • Cuyahoga Falls, Ohio, United States, 44223
      • Marion, Ohio, United States, 43302
      • Shaker Heights, Ohio, United States, 44120
      • Stow, Ohio, United States, 44224
    • Oklahoma
      • Oklahoma City, Oklahoma, United States, 73103
      • Oklahoma City, Oklahoma, United States, 73132
      • Oklahoma City, Oklahoma, United States, 73159
    • Oregon
      • Portland, Oregon, United States, 97220
    • Pennsylvania
      • Harrisburg, Pennsylvania, United States, 17112
      • Jersey Shore, Pennsylvania, United States, 17740
      • Philadelphia, Pennsylvania, United States, 19140
      • Philadelphia, Pennsylvania, United States, 19153
      • Upper Saint Clair, Pennsylvania, United States, 15241
    • South Carolina
      • Charleston, South Carolina, United States, 29414
      • Charleston, South Carolina, United States, 29412
      • Columbia, South Carolina, United States, 29201
      • Greer, South Carolina, United States, 29651
    • Tennessee
      • Germantown, Tennessee, United States, 38138
      • Jackson, Tennessee, United States, 38305
      • Murfreesboro, Tennessee, United States, 37130
      • New Tazewell, Tennessee, United States, 37825
    • Texas
      • Arlington, Texas, United States, 76012
      • Dallas, Texas, United States, 75231
      • Dallas, Texas, United States, 75230
      • Dallas, Texas, United States, 75235
      • Fort Worth, Texas, United States, 76117
      • Grand Prairie, Texas, United States, 75052
      • Houston, Texas, United States, 77074
      • Houston, Texas, United States, 77008
      • Houston, Texas, United States, 77081
      • Houston, Texas, United States, 77083
      • San Antonio, Texas, United States, 78229
      • San Antonio, Texas, United States, 78209
      • Sugar Land, Texas, United States, 77479
      • Sugar Land, Texas, United States, 77478
      • Tomball, Texas, United States, 77375
    • Utah
      • Salt Lake City, Utah, United States, 84107
      • Salt Lake City, Utah, United States, 84102
    • Virginia
      • Alexandria, Virginia, United States, 22304
      • Danville, Virginia, United States, 24541
      • Manassas, Virginia, United States, 20110
      • Richmond, Virginia, United States, 23225
      • Salem, Virginia, United States, 24153
      • Suffolk, Virginia, United States, 23435
    • Washington
      • Lakewood, Washington, United States, 98499
    • Wisconsin
      • Kenosha, Wisconsin, United States, 53142

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosis of Type 2 diabetes mellitus
  • Inadequate glycemic control on a stable dose (at least 2 months prior to screening) of pioglitazone at 30 or 45 mg/day, with or without one or two other oral antidiabetic medications [metformin or a sulfonylurea, or dipeptidyl peptidase (DPP-IV) inhibitor]
  • Hemoglobin A1c (HbA1c) >= 7.5% and =< 9.5% at screening
  • Fasting plasma glucose =<240 mg/dL at randomization (Week 0/Day 1).
  • Male or female >= 18 years of age.
  • Women of childbearing potential must be using an adequate method of contraception as detailed per-protocol
  • Fasting C-peptide level >0.5 ng/mL at screening
  • Clinically stable in regards to medical conditions other than type 2 diabetes
  • Concomitant medications are at stable doses for at least 30 days prior to enrollment, and are not anticipated to need adjustment during the study period

Exclusion Criteria:

  • History of Type 1 diabetes and/or history of ketoacidosis
  • History of bowel obstruction
  • History of hypertriglyceridemia-induced pancreatitis
  • Fasting serum triglyceride concentration >500 mg/dL
  • History of dysphagia, swallowing disorders, gastroparesis, other gastrointestinal motility disorders, major gastrointestinal surgery
  • History of insulin use >= 2 weeks duration during the previous 3 months or a total of >2 months insulin therapy at any time prior to screening
  • Treatment with bile acid sequestrants, including colesevelam within 3 months prior to screening
  • Female subject who is pregnant or breastfeeding
  • History of unstable angina, myocardial infarction, cerebrovascular accident, transient ischemic attack, or any revascularization within 6 months prior to screening

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Colesevelam
Participants receive six colesevelam tablets (3.8 grams/day) in addition to pioglitazone-based therapy (30 mg or 45 mg)
Colesevelam 625 mg tablets
Other Names:
  • Welchol
30 mg or 45 mg pioglitazone therapy
Other Names:
  • Actos
Placebo Comparator: Placebo
Participants receive six placebo tablets in addition to pioglitazone-based therapy (30 mg or 45 mg)
30 mg or 45 mg pioglitazone therapy
Other Names:
  • Actos
Placebo tablets appearing to be colesevelam
Other Names:
  • No drug

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24
Time Frame: Baseline, Week 24
Baseline, Week 24

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in HbA1c at Week 4
Time Frame: Baseline, Week 4
Baseline, Week 4
Change From Baseline in HbA1c at Week 8
Time Frame: Baseline, Week 8
Baseline, Week 8
Change From Baseline in HbA1c at Week 16
Time Frame: Baseline, Week 16
Baseline, Week 16
Number of Participants Achieving an HbA1c Goal of <7.0%
Time Frame: Week 24
Week 24
Change From Baseline in Fasting Plasma Glucose (FPG)
Time Frame: Baseline, Week 24
In this study a reduction in FPG of at least 30 mg/dL is considered glycemic response.
Baseline, Week 24
Number of Participants With a Decrease of >= 0.7 Percent in HbA1c
Time Frame: Week 24
Week 24
Number of Participants With a Decrease of >= 0.5 Percent in HbA1c
Time Frame: Week 24
Week 24
Number of Participants With a Reduction in FPG of >= 30 mg/dL
Time Frame: Week 24
Week 24
Percent Change From Baseline in Total Cholesterol (TC)
Time Frame: Baseline, Week 24
TC is measured in milligrams per deciliter (mg/dL)
Baseline, Week 24
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Time Frame: Baseline, Week 24
LDL-C is measured in mg/dL
Baseline, Week 24
Percent Change From Baseline in High-density Lipoprotein Cholesterol (HDL-C)
Time Frame: Baseline, Week 24
HDL-C is measured in mg/dL
Baseline, Week 24
Percent Change From Baseline in Non-HDL-C
Time Frame: Baseline, Week 24
Non-HDL-C is measured in mg/dL
Baseline, Week 24
Percent Change From Baseline in Triglycerides (TG)
Time Frame: Baseline, Week 24
TG are measured in mg/dL
Baseline, Week 24
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-I)
Time Frame: Baseline, Week 24
Apo A-1 is measured in mg/dL
Baseline, Week 24
Percent Change From Baseline in Apolipoprotein B (Apo B)
Time Frame: Baseline, Week 24
Apo B is measured in mg/dL
Baseline, Week 24
Change From Baseline in Fasting Insulin Levels
Time Frame: Baseline, Week 24
Baseline, Week 24
Change From Baseline in Fasting C-peptide
Time Frame: Baseline, Week 24
Baseline, Week 24
Change From Baseline in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
Time Frame: Baseline, Week 24
HOMA-IR is a calculation of fasting insulin and fasting glucose that shows the level of insulin resistance. Lower numbers are better.
Baseline, Week 24

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2009

Primary Completion (Actual)

July 1, 2012

Study Completion (Actual)

July 1, 2012

Study Registration Dates

First Submitted

November 10, 2008

First Submitted That Met QC Criteria

November 10, 2008

First Posted (Estimate)

November 13, 2008

Study Record Updates

Last Update Posted (Actual)

June 26, 2017

Last Update Submitted That Met QC Criteria

June 23, 2017

Last Verified

June 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe